Forecast

There is no analyst data available for this company.

News Go to news feed

PolyNovo achieves 26% revenue growth and shares rise after strong half-year report

PolyNovo reports group revenue of AUD 68.2m for H1 2026 (+26%) and adjusted EBITDA of AUD 4.7m (+82%), driven by strong growth in the US (75.8% of revenue) and 95 new hospital customers. The share price rose 5.72% to AUD 1.005; gross margin was temporarily pushed down to 88.8% by manufacturing optimization measures. The company plans to complete a new production facility by July 2026 and is preparing a PMA submission for a product to treat full-thickness burns. » More on de.investing.com
Polynovo shares jump sharply after CMS proposal for skin substitute reimbursement

Polynovo shares surged after a US CMS proposal for a uniform flat reimbursement of $806 per square inch for skin substitutes. Polynovo said its NovoSorb products should remain profitable under the new model; interim CEO Robyn Elliott sees significant growth potential in the outpatient market. A final decision is expected in November, with implementation planned for January 2026. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Polynovo has already paid €0.14 in dividends. The last payout was in May 2022.

Financials

In the last quarter, Polynovo had revenue of €44.45M and net profit of €4.44M

(EUR)	Jun 2026	YoY
Revenue	44.45M	-
Gross profit	15.44M	-
Net profit	4.44M	-
EBITDA	3.94M	-

Fundamentals

Metric	Value
Market capitalization	€423.53M
Number of shares	690.84M
52-week high/low	€0.88 - €0.47
Dividends	No
Beta	1.34
P/E ratio	98.11
PEG ratio	-2.20
P/B ratio	7.92
P/S ratio	5.00

Company profile

Polynovo Limited entwickelt Medizinprodukte in den Vereinigten Staaten, Australien, Neuseeland, dem Vereinigten Königreich, Irland, Singapur und international. Das Unternehmen bietet die biologisch abbaubare temporäre Matrix NovoSorb an, die in einer vollständig debridierten, sauberen chirurgischen Wunde verwendet wird, um die Wunde physiologisch zu schließen. Darüber hinaus entwickelt es Syntrel Hernienvorrichtungen für die Hernienreparatur, NovoSorb Dermal Beta Cell Implant, das Pankreasinseln in der Haut beherbergt, und NovoSorb Drug Elution Depots. Das Unternehmen war früher unter dem Namen Calzada Limited bekannt und änderte im November 2014 seinen Namen in Polynovo Limited. Polynovo Limited wurde 1998 gegründet und hat seinen Hauptsitz in Port Melbourne, Australien.